March 1, 2018 / 6:56 PM / 8 months ago

BRIEF-FibroGen Gets FDA Fast Track Designation For Its Pancreatic Cancer Treatment

March 1 (Reuters) - FibroGen Inc:

* UPDATE - FIBROGEN GRANTED FAST TRACK DESIGNATION BY U.S. FDA FOR PAMREVLUMAB TREATMENT OF PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE PANCREATIC CANCER

* FIBROGEN - FAST TRACK DESIGNATION FOLLOWS REVIEW OF CO'S PHASE 2 CLINICAL TRIAL EVALUATING PAMREVLUMAB IN COMBINATION WITH GEMCITABINE & NAB-PACLITAXEL Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below